IMO, they are going to want to see the common shareholder valuation obtain as high a fair market valuation as possible as THAT price determines the value of preferred and phantom shares which is huge part of equity compensation for insiders here and of course any new capital that enters is going to want to see a sustained valuation to support these assets through key phase 2 and phase 3 clinical trials, where 100+ million valuation can turn into billions... but gonna be hard to support anything trading for peanuts, with a revoked registration and a bunch of confused equity owners...
Hopefully KRM-ll-81 is inching closer and closer... Will BP jump in before that candidate takes off into clinicals?
Market Data 
Markets 
AI
